BidaskClub upgraded shares of GRIFOLS S A/S (NASDAQ:GRFS) from a buy rating to a strong-buy rating in a report issued on Tuesday, BidAskClub reports.

Several other research analysts also recently commented on the stock. Zacks Investment Research downgraded shares of Hammerson from a hold rating to a sell rating in a research report on Friday, May 24th. JPMorgan Chase & Co. downgraded shares of Sogou from a neutral rating to an underweight rating and lowered their price objective for the company from $5.50 to $4.12 in a research report on Thursday, June 27th. Three analysts have rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $20.75.

NASDAQ GRFS opened at $21.66 on Tuesday. The company has a current ratio of 2.87, a quick ratio of 1.13 and a debt-to-equity ratio of 1.41. GRIFOLS S A/S has a 1-year low of $17.42 and a 1-year high of $21.99. The company has a 50 day simple moving average of $19.62. The firm has a market capitalization of $15.00 billion, a P/E ratio of 18.51, a price-to-earnings-growth ratio of 1.30 and a beta of 1.16.

GRIFOLS S A/S (NASDAQ:GRFS) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.25. GRIFOLS S A/S had a net margin of 12.35% and a return on equity of 15.49%. The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. Research analysts predict that GRIFOLS S A/S will post 1.27 earnings per share for the current year.

The company also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, June 18th. Shareholders of record on Monday, June 10th were given a dividend of $0.14 per share. The ex-dividend date of this dividend was Friday, June 7th. GRIFOLS S A/S’s dividend payout ratio is currently 22.22%.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Raymond James & Associates grew its stake in shares of GRIFOLS S A/S by 75.9% during the fourth quarter. Raymond James & Associates now owns 20,090 shares of the biotechnology company’s stock worth $369,000 after buying an additional 8,670 shares during the last quarter. Advisor Group Inc. grew its stake in shares of GRIFOLS S A/S by 18.7% during the fourth quarter. Advisor Group Inc. now owns 25,065 shares of the biotechnology company’s stock worth $460,000 after buying an additional 3,941 shares during the last quarter. Northern Trust Corp grew its stake in shares of GRIFOLS S A/S by 4.3% during the fourth quarter. Northern Trust Corp now owns 544,975 shares of the biotechnology company’s stock worth $10,006,000 after buying an additional 22,602 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of GRIFOLS S A/S by 22.2% during the fourth quarter. Two Sigma Investments LP now owns 819,034 shares of the biotechnology company’s stock worth $15,037,000 after buying an additional 148,900 shares during the last quarter. Finally, Two Sigma Advisers LP grew its stake in shares of GRIFOLS S A/S by 502.7% during the fourth quarter. Two Sigma Advisers LP now owns 134,400 shares of the biotechnology company’s stock worth $2,468,000 after buying an additional 112,100 shares during the last quarter. Institutional investors and hedge funds own 19.01% of the company’s stock.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

Featured Story: What are momentum indicators and what do they show?

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.